WIE GEFAEHRLICH IST DIE SPLENEKTOMIE BEI M. HODGKIN. = DANGER DE LA SPLENECTOMIE DANS LA MALADIE DE HODGKINVON ROEMELING R; HARTWICH G; NEIDHARDT B et al.1978; FORTSCHR. D. MED.; DEU; DA. 1978; VOL. 96; NO 36; PP. 1816-1820; ABS. ENG; BIBL. 1 P.Article

BEHANDLUNGSERGEBNISSE AKUTER LEUKOSEN IM ERWACHSENENALTER MIT DEM TRAMPCO-SCHEMA = RESULTATS DU TRAITEMENT DES LEUCEMIES AIGUES DE L'ADULTE PAR LE SCHEMA TRAMPCOHARTWICH G; VON ROEMELING R; NEIDHARDT B et al.1979; MED. WELT; DEU; DA. 1979; VOL. 30; NO 50; PP. 1906-1909; BIBL. 11 REF.Article

Chemotherapy-induced vomiting: circadian drug timing as a source of predictable within-patient variabilityHRUSHESKY, W. J. M; VON ROEMELING, R.Cancer treatment reports. 1986, Vol 70, Num 11, pp 1347-1348, issn 0361-5960Article

INTESTINALE ANGIODYSPLASIE BEI V. WILLEBRAND-JUERGENS-SYNDROM ALS URSACHE MASSIVER GASTROINTESTINALER BLUTUNGEN = ANGIODYSPLASIE INTESTINALE DANS LE SYNDROME DE VON WILLEBRAND-JUERGENS CAUSE D'HEMORRAGIES GASTROINTESTINALES MASSIVESVON ROEMELING R; NEIDTHARDT B; KOENIG H et al.1980; MED. WELT; DEU; DA. 1980; VOL. 31; NO 15; PP. 540-544; BIBL. 27 REF.Article

Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusionVON ROEMELING, R; RABATIN, J. T; FRALEY, E. E et al.The Journal of urology. 1988, Vol 139, Num 2, pp 259-262, issn 0022-5347Article

Mandibular myelosarcoma (chloroma): primary oral manifestation of promyelocytic leukemiaREICHART, P. A; ROEMELING, R. V; KRECH, R et al.Oral surgery, oral medicine, oral pathology. 1984, Vol 58, Num 4, pp 424-427, issn 0030-4220Article

Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumorsSHULMAN, L. N; BUSWELL, L; RIESE, N et al.International journal of radiation oncology, biology, physics. 1999, Vol 44, Num 2, pp 349-353, issn 0360-3016Article

Chronotherapy of cancer : a major drug-delivery challengeHRUSHESKY, W. J. M; MARTYNOWICZ, M; MARKIEWICZ, M et al.Advanced drug delivery reviews. 1992, Vol 9, Num 1, pp 1-83, issn 0169-409XArticle

Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancerAGHAJANIAN, C; BROWN, C; O'FLAHERTY, C et al.Gynecologic oncology (Print). 1997, Vol 67, Num 2, pp 127-130, issn 0090-8258Article

Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksSENAN, S; RAMPLING, R; KAYE, S. B et al.Clinical cancer research. 1997, Vol 3, Num 1, pp 31-38, issn 1078-0432Article

Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumorsJOHNSON, C. A; KILPATRICK, D; VON ROEMELING, R et al.Journal of clinical oncology. 1997, Vol 15, Num 2, pp 773-780, issn 0732-183XArticle

Metabolic characterization of human soft tissue sarcomas in vivo and in vitro using proton-decoupled phosphorus magnetic resonance spectroscopyLI, C.-W; KUESEL, A. C; PADAVIC-SHALLER, K. A et al.Cancer research (Baltimore). 1996, Vol 56, Num 13, pp 2964-2972, issn 0008-5472Article

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancerMILLER, V. A; NG, K. K; GRANT, S. C et al.Annals of oncology. 1997, Vol 8, Num 12, pp 1269-1271, issn 0923-7534Article

Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer : an Eastern cooperative oncology group study. CommentaryGLAZIER, D. B; BAHNSON, R. R; MCLEOD, D. G et al.The Journal of urology. 1995, Vol 154, Num 1, pp 66-68, issn 0022-5347Article

Methylzene blue protects intestinal mucosa from free radical-mediated sublethal radiation damageHRUSHESKY, W. J. M; BERESTKA, J. S; VON ROEMELING, R et al.Free radical biology & medicine. 1988, Vol 5, Num 4, pp 207-213, issn 0891-5849Article

High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancerHRUSHESKY, W. J. M; ROEMELING, R. V; WOOD, P. A et al.Cancer treatment reports. 1987, Vol 71, Num 10, pp 915-919, issn 0361-5960Article

Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiencesROEMELING, R. V; OLSHEFSKI, R; LANGEVIN, T et al.Chronobiology international. 1986, Vol 3, Num 1, pp 55-64, issn 0742-0528Article

Sources of predictable tumor marker variation within the so-called normal range: circadian and circannual aspects of plasma carcinoembryonic antigen (CEA) in health and cancerTOUITOU, Y; SOTHERN, R. B; LEVI, F et al.Journal of tumor marker oncology. 1988, Vol 3, Num 4, pp 351-359, issn 0886-3849Article

Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiationDOHERTY, N; HANCOCK, S. L; KAYE, S et al.International journal of radiation oncology, biology, physics. 1994, Vol 29, Num 2, pp 379-382, issn 0360-3016Conference Paper

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer : A report of the international CATAPULT I study groupVON PAWEL, J; VON ROEMELING, R; OLVER, I et al.Journal of clinical oncology. 2000, Vol 18, Num 6, pp 1351-1359, issn 0732-183XArticle